Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization
Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization
复制标题
DOI：
10.1677/erc.1.01017
复制
发表时间：
2005-12-01
影响因子：
3.9
通讯作者：
Delle Fave, G
中科院分区：
文献类型：
--
作者：
Panzuto, F;Nasoni, S;Delle Fave, G
由于胃-肠-胰腺内分泌肿瘤是罕见的异质性疾病，其预后和长期生存率尚不清楚。本研究旨在确定胃-肠-胰腺内分泌肿瘤的预后因素并评估其长期生存率。共入组156例患者。通过单变量/多变量分析确定预后因素;通过Kaplan-Meier方法评估生存率。59.6%的患者肿瘤无功能，42.9%的患者起源于胰腺。诊断时，64.3%的患者有转移。89.6%的患者肿瘤分化良好。39.6%的患者Ki 67>2%。49.6%的病例原发肿瘤大小> 3 cm。单因素分析中，阴性预后因素为：胰腺来源（率比4.64，P= 0.0002），低分化肿瘤（率比7.70，P= 0.0001），原发肿瘤大小> 3cm（率比4.26，P= 0.0009），存在远处转移（肝脏：率比5.88，P=0.01;远处肝外：率比13.41，P= 0.0008）。多因素分析显示胰腺部位、低分化程度和远处转移为预后不良因素。总的5年生存率为77.5%。生存率根据以下因素而不同：原发肿瘤部位（胰腺为62%，胃肠道为89.9%，P = 0.0001）和大小（> 3 cm为65.7%，胃肠道为88.8%，
Since gastro-entero-pancreatic endocrine tumors are rare and heterogeneous diseases, their prognosis and long-term survival are not well known. This study aimed at identifying prognostic factors and assessing long-term survival in gastro-entero-pancreatic endocrine tumors. A total of 156 patients enrolled. Prognostic factors were determined by univariate/multivariate analysis; survival rates were assessed by the Kaplan-Meier method. The tumors were non-functioning in 59.6% of patients, and originated from the pancreas in 42.9%. At diagnosis, 64.3% of patients had metastases. The tumors were well differentiated in 89.6% of patients. Ki67 was >2% in 39.6% of patients. Primary tumor size was > 3 cm in 49.6% of cases studied. For the univariate analysis, the negative prognostic factors were: pancreatic origin (rate ratio 4.64, P= 0.0002), poorly differentiated tumor (rate ratio 7.70, P= 0.0001), primary tumor size >3 cm (rate ratio 4.26, P= 0.0009), presence of distant metastases (liver: rate ratio 5.88, P=0.01; distant extra-hepatic: rate ratio 13.41, P= 0.0008). The pancreatic site, the poor degree of differentiation and the distant metastases were confirmed as negative prognostic factors at multivariate analysis. Overall 5-year survival rate was 77.5%. Survival rates differed according to: primary tumor site (62% for pancreatic vs 89.9% for gastrointestinal tract, P = 0.0001) and size (65.7% for > 3 cm vs 88.8% for